About Ensemble


Chief Scientific Officer

Stephen Hale joined Ensemble Therapeutics in 2006. He is currently Senior Vice President, Biological Sciences and is responsible for advancing all in-house and partnered discovery programs. Ensemble’s in-house pipeline is oncology focused with a particular emphasis on the immune checkpoint and ubiquitin proteasome system (UPS) areas.

Prior to Ensemble, he was responsible for all biological aspects of the pre-clinical small molecule and peptidomimetic drug discovery programs at Praecis Pharmaceuticals. His role as a key inventor of the DNA-Encoded Library/Direct Select drug discovery platform and his involvement in the advancement of multiple pre-clinical candidate molecules in oncology were integral to the value generation that led to the acquisition of Praecis by GlaxoSmithKline plc.

Early in his career he was a founding scientist at Phylos Inc., where he had responsibilities in both the therapeutic and microarray areas. He was a leader in the development of a preclinical pipeline of protein therapeutics, namely antibodies and antibody-mimic molecules, and the concurrent development of diagnostic protein array products. He led the team responsible for the identification of a human fibronectin-based VEGF/KDR antagonist that was acquired and advanced into clinical development by Bristol Myers Squibb.

He has been a consultant to Cubist Pharmaceuticals and involved in early work at Genex Inc. on the design and engineering of single-chain antibodies for therapeutic and industrial applications. He has numerous publications in top-tier journals and is an inventor on 17 issued patents.

He received his Ph.D. in Biochemistry from the University of Maryland, College Park and was a NIH post-doctoral fellow at MIT under the direction of Dr. Paul Schimmel.